Fibromyalgia Drug Pipeline Market Research Report 2021 Featuring 13 Companies Developing Therapies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fibromyalgia – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This Fibromyalgia – Pipeline Insight, 2021 provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibromyalgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Fibromyalgia R&D. The therapies under development are focused on novel approaches to treat/improve Fibromyalgia.

Fibromyalgia Emerging Drugs Chapters

This segment of the Fibromyalgia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fibromyalgia Emerging Drugs

TNX-102: Tonix Pharmaceuticals

Tonix is developing TNX-102 SL as a potential treatment for the symptoms of Fibromyalgia. It is currently in Phase 3 clinical development. TNX-102 SL targets mechanisms which are associated with disturbed sleep. It is believed that increasing sleep quality in fibromyalgia may facilitate the body’s adaptive ability to modulate the perception of pain.

TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. The dose of TNX-102 SL being studied in fibromyalgia is two tablets, or 5.6 mg of cyclobenzaprine each night at bedtime.

IMC1: Virios Therapeutics

IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress Herpes Simplex Virus-1 (“HSV-1”) activation and replication, with the end goal of reducing viral mediated disease burden. MC-1 combines two specific mechanisms of action purposely selected to inhibit HSV-1 activation and replication, thereby keeping HSV-1 in a latent (dormant) state or “down-regulating” HSV-1 from a lytic (active) state back to latency.

The famciclovir component of IMC-1 inhibits viral DNA polymerase necessary for replication. The celecoxib component of IMC-1 inhibits both cyclooxegenase-2 (“COX-2”) and COX-1 enzymes, used by HSV-1 to accelerate its own replication. Virios Therapeutics holds a U.S. “Composition of Matter” Synergistic Patent (US 10,251,853) for the synergistic combination for total daily dose of famciclovir and celecoxib. The drug is being evalauated in Phase II stage of development for the treatment of Fibromyalgia.

Fibromyalgia: Therapeutic Assessment

This segment of the report provides insights about the different Fibromyalgia drugs segregated based on following parameters that define the scope of the report, such as:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fibromyalgia drugs?
• How many Fibromyalgia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibromyalgia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fibromyalgia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fibromyalgia and their status?
• What are the key designations that have been granted to the emerging drugs?

Major Players in Fibromyalgia

There are approx. 13+ key companies which are developing the therapies for Fibromyalgia. The companies which have their Fibromyalgia drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.

Companies Featured

• Tonix Pharmaceuticals
• Aptinyx
• Virios Therapeutics, Inc.
• Teva Pharmaceuticals
• Knop Laboratorios
• Integrated Tissue Dynamics, LLC
• Axsome
• Sorrento Therapeutics
• Imbrium Therapeutics
• Cytocom Inc.
• Cortene Inc.
• Intec Pharma
• Luye Pharma

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Fibromyalgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fibromyalgia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibromyalgia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibromyalgia drugs.

Fibromyalgia Report Insights

• Fibromyalgia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fibromyalgia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/4oxjli

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900